The failure of cell proliferation to be properly regulated is a hallmark of tumourigenesis. The retinoblastoma protein (pRb) pathway represents a key component in the regulation of the cell cycle and tumour suppression. Recent findings have revealed new levels of complexity reflecting a repertoire of post-translational modifications that occur on pRb together with its key effector E2F-1. Here we provide an overview of the modifications and consider the possibility of a 'code' that endows pRb with the ability to function in diverse physiological settings.
Introduction
The regulation of the G1 to S phase transition during the cell cycle is essential for correctly controlled cell proliferation. One of the key players in this process is the retinoblastoma protein (pRb). pRb is a tumour suppressor protein that is absent or functionally inactivated in at least a third of all human tumours (Weinberg, 1995) . One of the ways in which pRb has an essential role in proliferation control is through binding to and regulating its key effector, the E2F family of transcription factors. The E2F family coordinates the transcription of genes that are required for cell cycle progression. When bound to pRb, E2F-mediated transcriptional activity is reduced and cell cycle progression is prevented (Dyson, 1998; Trimarchi and Lees, 2002; .
The E2F family comprises eight family members (E2F-1-8) with different subunits exhibiting distinct activities with regard to cell cycle progression and apoptosis . With the exception of two family members (E2F-7 and E2F-8), E2F activity arises from the interaction of E2F with a DP binding partner, to form a transcriptionally active heterodimeric complex (Trimarchi and Lees, 2002) . For the purposes of this review we will focus on the most extensively investigated family member, E2F-1. Significantly, E2F-1 represents a paradox as it can act as both a tumour suppressor and an oncogene, and depending on the cellular signals transmitted, E2F-1 has the ability to stimulate proliferation or apoptosis Polager and Ginsberg, 2008) . This dual function necessitates that E2F-1 activity is tightly regulated during the cell cycle, which is accomplished in a variety of ways. For example, E2F-1 can upregulate its own transcription, its activity is modulated by interacting proteins, protein turnover is tightly controlled and E2F-1 is regulated by post-translational modifications (Dyson, 1998; Harbour and Dean, 2000; .
One of the most well-understood aspects of E2F regulation is the inactivation of its transcriptional activity via the interaction with pRb. The inhibition of E2F-1 activity, which occurs as a consequence of this interaction, coincides with the ability of pRb to arrest cells in G1 (Harbour and Dean, 2000) . During the cell cycle, as cells progress from the G1 to S phase, the sequential phosphorylation of pRb by cyclin/cyclindependant kinase (Cdk) complexes causes the release of E2F-1 and the activation of genes required for the entry into S phase (Sherr, 2000; Classon and Harlow, 2002; Longworth and Dyson, 2010) . pRb belongs to a family of proteins referred to as 'pocket proteins', which also includes the related proteins, p107 and p130 (Cobrinik, 2005) . These proteins are defined by a conserved pocket domain which serves as a binding site for numerous cellular proteins and viral oncoproteins (Cobrinik, 2005) . In addition to its wellestablished role in cell cycle progression, studies in Rb À/À mice highlighted an essential function for pRb in other cellular processes, such as differentiation and apoptosis (Clarke et al., 1992; Jacks et al., 1992) . In addition to binding E2F-1 and preventing its transcriptional activity, pRb can also actively repress transcription through targeting chromatin-remodelling enzymes, such as histone deacetylases and methyltransferases, and interact with chromatin-associated proteins to influence the chromatin environment (Longworth and Dyson, 2010) . The observation that pRb interacts with a wide range of chromatin-binding proteins and chromatin-modifying enzymes has led to the concept that pRb can exert global control upon chromatin, a notion which is strengthened by the fact that cells lacking pRb family members display altered chromatin states and exhibit chromosomal aberrations (Herrera et al., 1996; Gonzalo et al., 2005) .
The regulation of the pRb/E2F pathway by cyclin/ Cdk phosphorylation is intrinsic to cell cycle control. Cyclin/Cdk complexes are themselves negatively regulated by Cdk inhibitors such as p16  INK4A , p21  CIP1 and  p27 KIP1 (Sherr and Roberts, 2004) . Whilst phosphorylation is recognized as a post-translational modification that significantly influences pRb activity, it is now apparent that other types of modification can also impact upon pRb/E2F. For example, pRb and E2F-1 are modified on lysine residues by post-translational modifications such as acetylation, methylation, ubiquitination and SUMOylation.
Most of our knowledge of lysine acetylation and methylation has come from the studies on histones in chromatin control (Zhang and Reinberg, 2001) . The diversity and extent to which histones can be modified has led to the concept of the 'histone code' (Jenuwein and Allis, 2001 ). The 'histone code' suggests that the modification of histone tails is 'written' by one set of enzymes, 'read' by effector molecules and 'erased' by another set of enzymes (Jenuwein and Allis, 2001) . It is believed that chromatin control by 'readers, writers and erasers' enables fine-tuning in response to different physiological contexts. In simple terms, some posttranslational modifications are associated with transcriptional activation and others with repression, which is facilitated by recruiting 'reader' proteins, which then direct gene activity. Furthermore, additional levels of complexity exist as single residues can be targeted by more that one type of modification.
Most significantly, the concept of post-translational modifications creating a 'code' that can impart different biological activities may not be restricted to histones (Sims and Reinberg, 2008) . The p53 tumour suppressor protein is a particularly good example, where many of the enzymes that act upon histones also target p53. Thus, p53 can be modified by phosphorylation, acetylation, methylation, SUMOylation and NEDDylation (Meek and Anderson, 2009) . It is also clear that there is cross-talk between p53 modifications, where different combinations of modification can promote diverse outcomes (Meek and Anderson, 2009; Dai and Gu, 2010) .
Recent evidence suggests that pRb and E2F-1 are subjected to additional levels of post-translational control by phosphorylation, acetylation, methylation, SUMOylation and ubiquitination. Here, we will discuss advances in our understanding of the increasingly wide spectrum of post-translational modifications that act upon pRb and E2F-1, raising the possibility that a 'code' exists which provides greater levels of complexity on pRb, enabling it to function in diverse physiological roles.
pRb phosphorylation pRb is a nuclear phosphoprotein, and the phosphorylation of pRb on many sites by the cyclin/Cdks has been extensively documented (Mittnacht, 1998; Adams, 2001) . pRb harbours up to 16 potential Cdk consensus sites (Knudsen and Wang, 1996) (Figure 1 K 8 7 3 K 8 6 0 K 8 1 0 P S 7 9 5 P S 2 4 9 P S 8 2 1 P S 8 2 6 P S 6 1 2 P S 5 6 7 P T 3 7 3 P T 3 5 6 Diversity within the pRb pathway S Munro et al E2F-1, allowing E2F-1 to activate the transcription of genes required for DNA synthesis and cell cycle progression (Connell-Crowley et al., 1997; Mittnacht, 1998; Sherr, 2000) . It is believed that in early G1, cyclin D/Cdk4/6 phosphorylates pRb targeting S249, T356, S807, S811 and T826 (Zarkowska and Mittnacht, 1997) ; cyclin E/ Cdk2 targets pRb in late G 1 and early S phase phosphorylating S612 and T821. Inactive, hyperphosphorylated pRb is maintained by cyclin A/Cdk2 throughout the S phase and the rest of the cell cycle. The initial phosphorylation events occur in the C-terminal region and cause a conformational change in pRb, allowing an intramolecular interaction to occur with the central pocket region (Rubin et al., 2005) ; this interaction excludes HDAC binding to the pocket and thus prevents active transcriptional repression. The conformational changes that occur as a result of early phosphorylation events on pRb collectively lead to the interaction of pRb with cyclin E/Cdk2, which phosphorylates S567. As S567 is located in the core of the pocket region, phosphorylation of this residue prevents pRb from binding to and inactivating E2F-1 (Harbour et al., 1999) .
During mitotic exit, pRb is dephosphorylated by protein phosphatase 1 (PP1) (Ludlow et al., 1993) . A structural study examining the association between pRb and PP1 revealed an enzyme docking site in the Cterminal domain of pRb that is essential for PP1 activity towards pRb (Hirschi et al., 2010) . The phosphatase binding site maps to amino acid residues 870-882, which overlaps with a well-documented Cdk binding site (amino acid 868-878) (Schulman et al., 1998; Adams et al., 1999; Lowe et al., 2002) . PP1 competes with Cdkcyclins for pRb binding, maintains pRb in an active growth-suppressing form and blocks cell cycle progression (Hirschi et al., 2010) . pRb is also phosphorylated by a number of other protein kinases. For example, there have been reports that pRb is phosphorylated by p38 MAP kinase (Wang et al., 1999; Nath et al., 2003; Yeste-Velasco et al., 2009) . p38 is a stress-activated protein kinase which phosphorylates pRb on S567 (Delston et al., 2011) . Under conditions of DNA damage, p38 phosphorylates Rb, which then allows pRb to be targeted for degradation by Mdm2. Once pRb is degraded, E2F-1 is released and activates the genes required for apoptosis (Delston et al., 2011) .
A wide variety of DNA-damaging agents can induce the phosphorylation of pRb at S612 (Inoue et al., 2007) . This phosphorylation event is mediated by either checkpoint kinase, Chk1 or Chk2, reflecting the type of DNA damage. Phosphorylation events on pRb are normally associated with the inactivation of pRb and release of E2F-1; however, phosphorylation at S612 in response to DNA damage appears to represent an activating event. Indeed, S612 phosphorylation promotes the interaction between E2F-1 and pRb, and is required for pRb anti-apoptotic activity during the DNA damage response (Inoue et al., 2007) .
We do not have a complete understanding of the importance of individual residues and whether combinations of phosphorylation events result in particular outcomes. It is a widely accepted notion that inactivation of pRb requires its sequential phosphorylation by cyclin/Cdk complexes, although a number of studies suggest that this mechanism may not necessarily be general and widespread. A recent study adopting a more complex mutagenic approach found that phosphorylation of a single residue in the N-terminal region of pRb was capable of causing pRb inactivation (Lents et al., 2006; Gorges et al., 2008) . A mutational analysis in which each Cdk phosphorylation site was restored individually revealed T373 as a critical residue involved in pRb inactivation. Interestingly, it was also observed that the presence of the extreme C-terminal region of pRb was required for this phosphorylation event.
Acetylation of pRb
A further level of regulation on pRb is mediated by the targeted acetylation of lysine residues ( Figure 1 ). The p300 transcriptional co-activator acetylates pRb on the adjacent lysine residues K873/K874 (Chan et al., 2001a) , and acetylation is enhanced by the viral oncoprotein E1A, which recruits p300 and pRb into a multimeric protein complex. Acetylation of pRb impedes the phosphorylation of pRb by cyclin/Cdk complexes, which is perhaps not entirely unexpected as the site of acetylation falls within the motif believed to be required for binding Cdks (residues 868-878) (Adams et al., 1999; Lowe et al., 2002) . Acetylation of pRb at K873/K874 is under cell cycle control and increased levels of acetylation occur during S phase (Chan et al., 2001a) .
pRb has an essential and widespread role in differentiation (Clarke et al., 1992; Jacks et al., 1992; Gu et al., 1993) . For example, the role of pRb is well established in myogenesis, osteogenesis, adipogenesis and neurogenesis (Khidr and Chen, 2006) . Elevated levels of acetylated pRb are observed during differentiation (Chan et al., 2001a; Nguyen et al., 2004; Pickard et al., 2010) . Acetylated pRb increases during myogenesis where the increase in acetylation coincides with pRb hypophosphorylation (Nguyen et al., 2004) . Like p300, the p300-associated factor (P/CAF) is also required for differentiation (Puri et al., 1997) , and a role for P/CAF as a potential pRb histone acetyltransferase during differentiation has been suggested. Through its pocket region, pRb interacts with the histone acetyltransferase domain of P/CAF and during differentiation the interaction is enhanced. Acetylated pRb cooperates with the transcription factor MyoD in achieving permanent growth arrest (Nguyen et al., 2004) . It has been suggested that pRb regulates MyoD activity by binding to and sequestering proteins that inhibit MyoD activity, such as the E1A-like inhibitor of differentiation (EID-1). During terminal differentiation, EID-1 forms a trimeric complex with pRb and Mdm2. Mdm2 mediates the ubiquitination and degradation of EID-1, which in turn relieves repression exerted upon MyoD, allowing the activation of genes required for differentiation (MacLellan et al., 2000; Miyake et al., 2000) . SignifiDiversity within the pRb pathway S Munro et al cantly, acetylated pRb exhibits increased affinity for Mdm2, and by recruiting Mdm2 to the complex, acetylated pRb promotes the degradation of EID-1, which ultimately leads to cell cycle exit and the transcription of genes required for differentiation (Chan et al., 2001a; Nguyen et al., 2004) .
During the DNA damage response, pRb undergoes increased acetylation at K873/K874 (Markham et al., 2006) . Treatment of cells with etoposide triggers a temporal induction in levels of acetylated pRb. In addition to the pocket-dependant interaction with E2F-1, pRb harbours a second E2F-1 interaction domain, which is situated in the C-terminal domain of pRb (Dick and Dyson, 2003) . DNA damage-dependant acetylation of pRb releases E2F-1 from the C-terminal interaction domain (Markham et al., 2006) , which is a separate interface to the pocket-dependant interaction. The importance of this regulatory mechanism has yet to be established, but a possibility is that it has a part in E2F-1-dependant apoptosis that occurs in response to DNA damage, perhaps facilitating the regulation of genes required for apoptosis.
Tip60, a member of the MYST histone acetyltransferase family, can also acetylate pRb. The lysine residues targeted by Tip60 remain to be identified, but as the pRb mutant derivative K873/K874 could still be acetylated, it seems that the residues targeted by Tip60 are distinct from those acetylated by p300 and P/CAF (Leduc et al., 2006) . Tip60 interacts with pRb and this triggers its degradation by the proteasome (Leduc et al., 2006) . Further, through an unknown mechanism the tumour suppressor protein, p14
ARF prevents Tip60 acetylation of pRb and in turn prevents its degradation (Leduc et al., 2006) .
A recent study in which the scope of lysine acetylation at the proteome-wide level was examined revealed further sites of acetylation on pRb at K427, K548, K640, K653 and K896 (Choudhary et al., 2009) . The functional relevance of these events awaits further investigation, but given that four of these residues are located in the vicinity of the pocket region of pRb it is possible that they could affect interactions with proteins that bind to the pRb pocket, with wide ranging consequences. It is interesting to note that the acetylation of lysine residues can create binding sites for proteins harbouring the protein module known as the bromodomain (Yang, 2004) . It is therefore tempting to speculate that acetylated pRb could perhaps recruit a bromodomain-containing protein; moreover, the binding of such a 'reader' protein could potentially influence the downstream response.
Lysine acetylation is a reversible process. SIRT1 (sirtuin 1) can interact with and deacetylate pRb (Wong and Weber, 2007) . SIRT1 is the human homologue of yeast silent information regulator 2; it is a class III HDAC subunit and its activity is regulated by the cofactor NAD þ . SIRT1 deacetylates a number of residues on histone proteins and more recently has been shown to deacetylate a wide range of non-histone proteins, including p53, p73, androgen receptor and Foxo proteins (Fang and Nicholl, 2011) . SIRT1 interacts with pRb and the related pocket proteins, p107 and p130 (Wong and Weber, 2007) . A marked reduction in pRb acetylation was observed when SIRT1 was introduced into cells at increasing levels, and omission of NAD þ failed to reduce pRb acetylation (Wong and Weber, 2007) , suggesting that SIRT1 can act as an 'eraser' to remove the acetylation signals present on pRb.
pRb methylation
The regulation of protein function by methylation has been an area of intense interest in recent years. Methylation by methyltransferases can occur on both lysine and arginine residues. A large number of methyltransferases have been identified, which can loosely be divided into two subgroups; lysine methyltransferases, mostly belonging to the SET domain family (Martin and Zhang, 2005) , and arginine methyltransferase, referred to as protein arginine dimethyltransferases (Bedford and Clarke, 2009 ). Very interestingly, pRb is methylated by the mono-methyltransferase Set7/9 at two distinct lysine residues within the C-terminal domain of pRb, K873 and K810 (Munro et al., 2010; Carr et al., 2011) (Figure 1 ). Methylation of pRb at K873 creates a binding site for the heterochromatin protein, HP1. HP1 is involved with gene silencing and transcriptional inactivity (Fischle et al., 2003; Hediger and Gasser, 2006) , and indeed when methylation of pRb is prevented an increase in the expression of E2F target genes such as DHFR, Cdc6 and E2F-1 occurs (Munro et al., 2010) . In addition, methylation at K873 can influence cell cycle progression; a mutant-derivative pRb lacking methylation at K873 displayed reduced ability to cause cell cycle arrest when compared with the wild-type counterpart. These results indicate that methylation at K873 enhances pRb activity, which in turn causes cell cycle arrest.
Further, pRb is an important player in the induction of cellular senescence and differentiation, which is tightly linked to its role as a tumour suppressor (Templeton et al., 1991) . Derivatives of pRb compromised in methylation were less efficient at inducing senescence and differentiation in cells compared with wild-type pRb (Chan et al., 2001a; Nguyen et al., 2004) , and the depletion of Set7/9 resulted in a reduced ability of cells to differentiate. Taken together, these results are suggestive of a role for pRb methylation in regulating cell fate, and identify Set7/9 as a 'writer' and HP1 as a 'reader' in regulating the properties of pRb.
The interplay between different types of post-translational modification in pRb is nicely illustrated by recent reports on lysine methylation at K810. K810 lies within a Cdk consensus motif and is flanked by S807 and S811, and methylation of K810 prevents phosphorylation of the juxtapositioned sites (Carr et al., 2011) (Figure 1 ). During the DNA damage response, pRb is predominantly hypophosphorylated (Knudsen et al., 2000) . Consequently, it was hypothesized that this scenario might influence methylation at K810. When cells were Diversity within the pRb pathway S Munro et al treated with DNA-damaging agents, the anticipated decrease in phosphorylation of pRb contrasted with the increased methylation at K810. A mutant derivative of pRb, which could not be methylated at K810, exhibited reduced DNA binding to E2F-regulated promoters and furthermore failed to cause cell cycle arrest (Carr et al., 2011) . Structural modelling suggested that methylation at K810 would physically preclude the interaction between pRb and Cdks, explaining the reduced level of Cdk-dependant phosphorylation. Interestingly, the effects of K810 methylation were not restricted to just S807 and S811, as methylation of K810 appeared to affect global phosphorylation of pRb, influencing phosphorylation of distant sites located in the N-terminal region of pRb, such as S249 and T252. The mechanism underlying the impact that methylation at K810 has on the global phosphorylation of pRb remains to be determined. However, it is feasible that phosphorylation of S807/S811 is a priming event that is a prerequisite for subsequent phosphorylation events on pRb at distant Cdk phoshorylation sites. Equally, it is possible that methylation at K810 introduces a site for a 'reader' protein, the binding of which excludes access of Cdk to distal phosphorylation sites. The direct methylation of K810 thus provides an additional level through which pRb phosphorylation can be regulated, and an example of the interplay that can occur between different levels of control (Figure 2 ). SMYD2 is a Set domain-containing protein first identified as a H3K36 dimethyltransferase (Brown et al., 2006) . SMYD2 possesses growth-suppressing properties and exists in complex with Sin3A and HDAC (Brown et al., 2006) . SMYD2 mono-methylates pRb on K860 during cell cycle exit, differentiation and during DNA damage (Saddic et al., 2010) . In a similar manner to the methylation at K873 and K810, methylation of K860 by the 'writer' SMYD2 caused a reduction in the expression of E2F target genes. Mono-methylation at K860 creates a binding site for L3MBTL1, a histone methyl-binding protein capable of condensing chromatin and repressing gene expression (Bonasio et al., 2010) . L3MTL1 contains three MBT domains that bind to mono-and dimethylated lysine residues (Min et al., 2007) . Methylation of K860 by SMYD2 is 'read' by L3MBTL1, which augments pRb growth regulation (Saddic et al., 2010) . Given that the location of K860 is very close to the Cdk docking site, it is conceivable that its methylation could also hinder phosphorylation of pRb.
Other pRb post-translational modifications
Lysine residues can be modified by the covalent attachment of ubiquitin and ubiquitin-like proteins (Pickart and Eddins, 2004) . Mdm2 is a member of the RING finger family of E3 ligases, which by binding to E2 ubiquitin-conjugating enzymes promotes the ubiquitination of target proteins. Mdm2 has previously been shown to interact with pRb (Xiao et al., 1995) and ubiquitinate pRb in vivo (Uchida et al., 2005) . The location of ubiquitination has yet to be defined, although the evidence suggests that it is located within the C-terminal region (Uchida et al., 2005) . Ubiquitination by Mdm2 facilitates pRb degradation via the ubiquitin-proteasome pathway (Uchida et al., 2005) . As loss of pRb is associated with uncontrolled cell Diversity within the pRb pathway S Munro et al proliferation and oncogenesis it was perhaps not surprising that an inverse relationship between Mdm2 and pRb was observed in lung cancer biopsies; high levels of Mdm2 correlated with low levels of pRb, arguing that Mdm2 may influence pRb in lung cancer in situ (Uchida et al., 2005) . As ubiquitination occurs in the C-terminal region of pRb, which is heavily modified by other post-translational modifications (Figure 1) , it is possible that interplay exists between ubiquitination and other modifications such as phosphorylation, acetylation and methylation. SUMO (small ubiquitin-related modifier) is a reversible post-translational modification, and many of its protein targets include transcriptional regulators (Muller et al., 2001 (Muller et al., , 2004 Wilkinson and Henley, 2010) . pRb is SUMOylated in the B domain of the pocket region on K720 (Ledl et al., 2005) (Figure 1) , within a cluster of lysine residues that are essential for the interaction with LXCXE motif-containing proteins (Chan et al., 2001b) . SUMOylation is regulated by the interaction of pRb with certain LXCXE-motif containing proteins, including EID-1 and the viral oncoproteins E1A and HPV E7, which bind to pRb via LxCxE motifs and prevent SUMOylation (Ledl et al., 2005) . SUMOylation preferentially occurs on hypophosphorylated pRb, and may disrupt the pRb/E2F-1 interaction (Ledl et al., 2005) .
Regulation of E2F-1 activity by phosphorylation
Phosphorylation of E2F-1 can also influence the pRb/ E2F-1 interaction, and in this respect several phosphorylation events on E2F-1 have been identified. E2F-1 is phosphorylated on S332 and S337, which prevent its interaction with pRb (Fagan et al., 1994; Sahin and Sladek, 2010) . p38 MAP kinase targets S403 and S433, and this is important for E2F-1 export from the nucleus and subsequent degradation (Ivanova et al., 2009) . Whilst E2F activity is positively regulated indirectly by cyclin D and cyclin E through their action upon pRb, E2F-1 is also under negative regulation by cyclinA/ Cdk2, and as cells enter S phase, E2F-1 binds to cyclinA/Cdk2, allowing the phosphorylation of DP-1 and inhibition of E2F binding ability (Xu et al., 1994) .
It has been shown that DNA damage-responsive kinases can phosphorylate E2F-1. Several studies found that E2F-1 protein levels are induced in response to DNA damage (Blattner et al., 1999; Lin et al., 2001; . E2F-1 is phosphorylated on S31 by ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related (ATM/ATR) kinases (Lin et al., 2001) . A yeast two hybrid screen in which a small N-terminal region of E2F-1 (containing S31) was used as the 'bait' isolated TopBP1 (DNA topoisomerase IIb binding protein 1) as a protein that could interact with E2F-1 (Liu et al., 2003) . TopBP1 contains eight BRCT motifs and it is through the sixth motif that it forms an interaction with E2F-1, an association which is induced by DNA damage and dependant upon phosphorylation of S31 (Liu et al., 2003) . Many E2F-1 activities are downregulated upon its association with TopBP1, including transcription, induction of S phase and apoptosis (Liu et al., 2003) . Mechanistically, it is believed that the recruitment of Brg1/Brm (a subunit of the SWI/SNF chromatin-remodelling complex) to the TopBP1/E2F-1 complex leads to the repression of E2F-1 regulated promoters .
The functional significance of phosphorylation events in E2F-1 is well illustrated by studies on 14-3-3 proteins. The 14-3-3 family member, 14-3-3t specifically binds to phosphorylated S31 (Wang et al., 2004) . In this regard, binding to 14-3-3 during DNA damage promotes E2F-1 stabilization by inhibition of ubiquitination, which is required for the expression of E2F-1 apoptotic target genes and doxorubicin-induced apoptosis (Wang et al., 2004) . In another study, E2F-1 levels were found to increase in response to etoposide and UV treatment in cells. A key component of the DNA-damage signalling pathway, Chk2, was identified as the kinase responsible for phosphorylating E2F-1 at S364, resulting in increased protein stability and apoptosis .
E2F-1 acetylation
E2F-1 is acetylated by the histone acetyltransferases p300 and P/CAF (Trouche et al., 1996; Martinez-Balbas et al., 2000; Marzio et al., 2000) . Acetylation of E2F-1 enhances DNA binding ability, transcriptional activity and protein stability (Martinez-Balbas et al., 2000; Marzio et al., 2000) . The residues acetylated by P/CAF and p300 lie close to the DNA binding domain (Figure 1 ). Given the enhanced DNA binding activity, it is possible that acetylation influences the structure of E2F-1 to facilitate contact with DNA. Acetylation of E2F-1 is induced by DNA-damaging agents, and treatment of cells with chemotherapeutic agents like doxorubicin induce E2F-1 acetylation (Pediconi et al., 2003) . A mutated protein that mimicked acetylation showed much higher apoptotic activity than the wildtype E2F-1 protein, perhaps reflecting its ability to bind and activate the genes required for apoptosis (Pediconi et al., 2003) .
Ubiquitination of E2F-1
The regulation of E2F-1 protein stability is central to E2F-1 control, and many of the modifications that target E2F-1 are known to influence E2F-1 turnover. E2F-1 is stabilized by DNA damage-dependant phosphorylation and acetylation events, which is believed to inhibit E2F-1 degradation mediated by the ubiquitinproteasome pathway (Lin et al., 2001; Pediconi et al., 2003; . As cells progress from S phase into G2, E2F-1 undergoes rapid degradation mediated by the F-box-containing protein p45 SKP2 , which is the cell cycle-regulated component of the ubiquitin-protein ligase SCF SKP2 (Jackson and Eldridge, 2002) . Upon completion of S phase, Skp2 binds to the N-terminal region of E2F-1 and targets it for degradaDiversity within the pRb pathway S Munro et al tion by the 26S proteasome (Marti et al., 1999) . However, the interaction of E2F-1 with certain proteins can impact on its ubiquitination and degradation. For example, E2F-1 interacts with p14 ARF , which upregulates E2F-1 ubiquitination and promotes its degradation (Martelli et al., 2001) . The Mdm2 protein has a surprising role in the regulation of E2F-1 ubiquitination; it binds to E2F-1, increasing its half-life by displacing p45 SKP2 . Interestingly, although a negative regulator of E2F-1, binding to pRb protects E2F-1 from ubiquitination and subsequent degradation (Campanero and Flemington, 1997) . Overall, therefore, E2F-1 ubiquitination appears to be regulated on several levels. The theme that emerges implies that a balance exists between different modifications and interacting proteins that determine E2F-1 protein stability.
Methylation of E2F-1
The histone methyltransferase Set7/9 methylates E2F-1 (Kontaki and Talianidis, 2010) . Set7/9 methylates E2F-1 at K185, which although located within the DNA binding domain of E2F-1, does not affect DNA binding activity in in vitro assays. There appears to be considerable interplay between methylation and other post-translational modifications; for example, methylation of E2F-1 antagonizes the acetylation and phosphorylation events that are required for its stabilization during the damage response, and methylation triggers ubiquitination and subsequent degradation of E2F-1 (Kontaki and Talianidis, 2010) . Methylation of E2F-1 is reduced upon DNA damage, where the demethylation event is likely to be mediated by the lysine-specific demethylase, LSD1, which reinstates E2F-1 apoptotic activity (Kontaki and Talianidis, 2010) . Given the interplay with ubiquitination, it is possible that methylation of E2F-1 acts as a pivotal mechanism to maintain E2F-1 levels at an appropriate level for normal cell cycle progression. Under conditions such as DNA damage, removal of the methyl mark and subsequent phosphorylation or acetylation events stabilize E2F-1, allowing the transcription of apoptotic genes.
Conclusions
The broad range of post-translational modifications that occur on pRb and E2F-1 suggests that parallels can be drawn with the modifications of histone tails, whereby a particular modification either acting alone or in concert contributes to a code, which thereafter imparts a function on the protein (Jenuwein and Allis, 2001; Sims and Reinberg, 2008) . Many of the enzymes that have previously been shown to act upon histone tails also modify pRb and E2F-1 (Tables 1 and 2 ). As the chromatin modifications that these 'writers' impart on histones direct transcriptional activity, it is possible that similar modifications of pRb/E2F-1 act in an analogous fashion, to impose different consequences on the pRb/ E2F pathway.
Several of the modifications on pRb/E2F-1 described to date occur in response to genotoxic stress and therefore it is worth considering the potential interplay that may occur between the different types of events under DNA damage. Thus, E2F-1 is phosphorylated by DNA damage-responsive kinases (Lin et al., 2001; Pediconi et al., 2003; . Although formal proof is lacking, it seems very likely that interplay will occur under these conditions. It is tempting to speculate that the extent of DNA damage is reflected in the degree to which E2F-1 is modified. For example, phosphorylation of S31 might recruit TopBP1 and halt S phase progression, allowing DNA repair to take place. On the other hand, if the extent of DNA damage is too extreme to repair, phosphorylation together with acetylation might prompt the transcriptional activation of apoptotic genes (Figure 3 ). In addition, pRb is methylated at K810 in response to DNA damage, which antagonizes its phosphorylation. Perhaps during DNA damage, methylated pRb turns off the expression of genes required for cell cycle progres- Prevents pRb phosphorylation, promotes differentiation Augments pRb repression K874 Acetylation p300, P/CAF Prevents pRb phosphorylation, promotes differentiation Diversity within the pRb pathway S Munro et al sion, while the modifications that occur on E2F-1 initiate an apoptotic response (Figure 3 ). Post-translational modifications can hinder or assist the occurrence of other post-translational modifications. In the case of E2F-1, methylation at K185 prevents phosphorylation and acetylation, and promotes ubiquitination (Kontaki and Talianidis, 2010) . Likewise, when pRb is targeted by methylation and acetylation, phosphorylation is reduced. Further, methylated lysine residues can serve as docking sites for 'reader' effector proteins such as HP1 and L3MBTL1, which have both been shown to bind to methylated pRb and augment repression activity (Munro et al., 2010; Saddic et al., 2010) (Figure 3) .
It is becoming increasingly clear that a variety of nonhistone proteins are regulated by a code that dictates an important level of control that enables information beyond the primary amino acid sequence to be imparted on the biological activity of a protein. Post-translational modifications acting in concert with 'reader' proteins on pRb are likely to coordinate protein function in such a manner that imparts diversity on its biological activity. As the pRb/E2F pathway has an integral role in many physiological processes, we can be confident that the range of post-translational modifications that have been documented to date are likely to reflect an increasingly complex repertoire of modifications that allow the pathway to orchestrate its extensive biological cues. Figure 3 Differential regulation of pRb/E2F-1 by post-translational modifications. Three scenarios are shown that result in different outcomes for the cell; cell cycle progression, cell cycle arrest and apoptosis. The enzymes regulating these events are shown; namely 'writers' (blue) and 'erasers' (orange). When pRb is methylated, it is envisaged that the binding of 'readers' (red), including HP1 and L3MBTL1, allow pRb to repress the transcription of E2F-1 target genes, thus permitting cell cycle arrest, differentiation and senescence. Ac: acetylation; Me, methylation; P, phosphorylation.
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